CNX Therapeutics Overview
- Year Founded
-
1997
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Fund - Cont Trans
- Financing Rounds
-
5
- Investments
-
6
CNX Therapeutics General Information
Description
Manufacturer of specialty pharmaceutical products intended to improve the lives of patients with neurological, psychiatric, and critical care conditions. The company licenses, commercializes, and distributes prescription medicines for central nervous system disorders, critical care, oncology, and hospital settings through strategic partnerships and pan-European distribution networks, enabling healthcare providers, hospitals, and pharmaceutical partners to improve patient access to essential medicines across global markets.
Contact Information
Website
www.cnx-therapeutics.comCorporate Office
- LABS House
- 15-19 Bloomsbury Way
- London WC1A 2TH
- England, United Kingdom
Corporate Office
- LABS House
- 15-19 Bloomsbury Way
- London WC1A 2TH
- England, United Kingdom
CNX Therapeutics Timeline
CNX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CNX Therapeutics Patents
CNX Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4626411-A1 | Cannabinoids for treating essential tremor in patients | Pending | 02-Dec-2022 | ||
| US-20260199377-A1 | Cannabinoids for treating essential tremor in patients | Pending | 02-Dec-2022 | ||
| EP-4514339-A1 | Treatment of spasticity and pain in renally-impaired patients | Pending | 27-Apr-2022 | ||
| US-20250262228-A1 | Treatment of spasticity and pain in renally-impaired patients | Pending | 27-Apr-2022 | ||
| US-8771760-B2 | Method for the treatment of constipation | Inactive | 27-Apr-2005 | A61K31/658 |
CNX Therapeutics Signals
CNX Therapeutics Investments (6)
CNX Therapeutics’s most recent deal was a Buyout/LBO with Sativex. The deal was made on 30-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sativex | 30-Oct-2025 | Buyout/LBO | Drug Discovery | ||
| Eisai (Two Central Nervous System Products) | 28-Mar-2024 | Buyout/LBO | Buildings and Property | ||
| Sanofi (Panacod Medicine in Sweden) | 30-Nov-2023 | Buyout/LBO | Buildings and Property | ||
| Sanofi (Propavan) | 30-Nov-2023 | Buyout/LBO | Buildings and Property | ||
| Clinigen (Portfolio of Established Medicines) | 09-Aug-2023 | Buyout/LBO | Pharmaceuticals |
CNX Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cnx Therapeutics Ireland | Dublin, Ireland | 2023 | |
| CNX Therapeutics Netherlands | Amsterdam, Netherlands | 2018 |
CNX Therapeutics FAQs
-
When was CNX Therapeutics founded?
CNX Therapeutics was founded in 1997.
-
Where is CNX Therapeutics headquartered?
CNX Therapeutics is headquartered in London, United Kingdom.
-
What is the size of CNX Therapeutics?
CNX Therapeutics has 70 total employees.
-
What industry is CNX Therapeutics in?
CNX Therapeutics’s primary industry is Pharmaceuticals.
-
Is CNX Therapeutics a private or public company?
CNX Therapeutics is a Private company.
-
What is CNX Therapeutics’s current revenue?
The current revenue for CNX Therapeutics is .
-
How much funding has CNX Therapeutics raised over time?
CNX Therapeutics has raised $4.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process